Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ—US Stock Market Updates: CoreWeave, Travelers, Tesla
Bank of America Hartnett: "Still inclined toward risk aversion" in the coming weeks, as US Treasuries set a four-year record for longest inflow streak
U.S. equity funds attracted $39 billion in inflows in a single week, pushing the annualized scale toward a historic high, while U.S. Treasuries also saw capital inflows for 16 consecutive weeks. However, Bank of America strategist Hartnett warns that due to rising real yields, the performance of AI and banking stocks, and the volatility of the midterm elections, there is still a preference for risk aversion in the coming weeks.
RBC Cuts Price Target on Equifax to $177 From $194, Keeps Outperform Rating
Crypto prices
More
